[
    [
        {
            "time": "2023-10-05",
            "original_text": "AbbVie Is Mizuho’s Top Pick Among Large-Cap Biopharma Stocks",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Mizuho",
                    "Top Pick",
                    "Large-Cap",
                    "Biopharma"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biopharma"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Is Mizuho’s Top Pick Among Large-Cap Biopharma Stocks",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease",
            "features": {
                "keywords": [
                    "Risankizumab",
                    "SKYRIZI®",
                    "Clinical Remission",
                    "Endoscopic Response",
                    "Phase 3",
                    "Crohn's Disease"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "3 Biotech Technological Developments to Watch Out For in 2021",
            "features": {
                "keywords": [
                    "Biotech",
                    "Technological Developments",
                    "Watch Out For",
                    "2021"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotech"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "3 Biotech Technological Developments to Watch Out For in 2021",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 4,
                "Headline_Structure": 6,
                "Source_Recency": 3
            }
        }
    ]
]